AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)

A Shteingauz, Y Porat, T Voloshin… - Cell death & …, 2018 - nature.com
Abstract Tumor Treating Fields (TTFields), an approved treatment modality for glioblastoma,
are delivered via non-invasive application of low-intensity, intermediate-frequency …

[HTML][HTML] Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy

NK Karanam, L Ding, A Aroumougame, MD Story - Translational Research, 2020 - Elsevier
Tumor treating fields (TTFields) is a noninvasive physical modality of cancer therapy that
applies low-intensity, intermediate frequency, and alternating electric fields to a tumor …

Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis

MT Ballo, P Conlon, G Lavy-Shahaf, A Kinzel… - Journal of Neuro …, 2023 - Springer
Abstract Purpose Tumor Treating Fields (TTFields) therapy, an electric field-based cancer
treatment, became FDA-approved for patients with newly diagnosed glioblastoma (GBM) in …

Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair …

NK Karanam, K Srinivasan, L Ding, B Sishc… - Cell death & …, 2017 - nature.com
The use of tumor-treating fields (TTFields) has revolutionized the treatment of recurrent and
newly diagnosed glioblastoma (GBM). TTFields are low-intensity, intermediate frequency …

A review on tumor-treating fields (TTFields): clinical implications inferred from computational modeling

C Wenger, PC Miranda, R Salvador… - IEEE reviews in …, 2018 - ieeexplore.ieee.org
Tumor-treating fields (TTFields) are a cancer treatment modality that uses alternating electric
fields of intermediate frequency (~ 100-500 kHz) and low intensity (1-3 V/cm) to disrupt cell …

Permeabilizing cell membranes with electric fields

AA Aguilar, MC Ho, E Chang, KW Carlson, A Natarajan… - Cancers, 2021 - mdpi.com
Simple Summary The FDA recently approved a fourth approach (in addition to surgery,
radiation therapy, and chemotherapy) for treating glioblastoma; namely, tumor treating fields …

Tumor Treating Fields (TTFields) concomitant with immune checkpoint inhibitors are therapeutically effective in non-small cell lung cancer (NSCLC) in vivo model

Y Barsheshet, T Voloshin, B Brant, G Cohen… - International Journal of …, 2022 - mdpi.com
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt
cellular processes critical for cancer cell viability and tumor progression. TTFields induce …

The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy

G Tanzhu, L Chen, G Xiao, W Shi, H Peng… - Cell Death …, 2022 - nature.com
Abstract Tumor Treating Fields (TTFields) is a physical therapy that uses moderate
frequency (100–300 kHz) and low-intensity (1–3 V/cm) alternating electric fields to inhibit …

Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis

L Berkelmann, A Bader, S Meshksar, A Dierks… - Scientific reports, 2019 - nature.com
Tumour-treating fields (TTFields) use alternating electric fields which interfere with dividing
cells, thereby reducing tumour growth. Previous reports suggest that electrical forces on cell …

[HTML][HTML] Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α in lung cancer

J Li, Y He, Z Tan, J Lu, L Li, X Song, F Shi, L Xie… - Theranostics, 2018 - ncbi.nlm.nih.gov
Hotspot mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) have been studied in
several cancers. However, the function of wild-type IDH2 in lung cancer and the mechanism …